Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy

Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy

Tumor microenvironment (TME) takes critical roles in tumor resistance to immune checkpoint inhibitors (ICIs) including anti-programmed death-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1). Cancer stem cells (CSCs) are one of the key components of TME that play important roles in immunoregulation...

Full description

Bibliographic Details
Main Authors:	Elnaz Rouzbahani, Jamal Majidpoor, Sajad Najafi, Keywan Mortezaee
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	Cancer stem cell (CSC) Programmed death-ligand 1 (PD-L1) Programmed death-1 (PD-1) Transforming growth factor-β (TGF-β) Immune checkpoint inhibitor (ICI) Tumor microenvironment (TME)
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332222012951

Similar Items

The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
by: Sajad Najafi, et al.
Published: (2023-05-01)

The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy
by: Keywan Mortezaee, et al.
Published: (2023-06-01)

Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitors
by: Keywan Mortezaee, et al.
Published: (2023-06-01)

Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies
by: Keywan Mortezaee, et al.
Published: (2023-02-01)

Anti-PD-(L)1 therapy of non-small cell lung cancer–A summary of clinical trials and current progresses
by: Keywan Mortezaee, et al.
Published: (2023-03-01)

Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
by: Keywan Mortaezaee, et al.
Published: (2023-07-01)

Advances in dendritic cell vaccination therapy of cancer
by: Sajad Najafi, et al.
Published: (2023-08-01)

Checkpoint inhibitor/interleukin‐based combination therapy of cancer
by: Keywan Mortezaee, et al.
Published: (2022-08-01)

Alternative immune checkpoints in immunoregulatory profile of cancer stem cells
by: Keywan Mortezaee, et al.
Published: (2023-12-01)

Immune checkpoint inhibitors in sarcomas: a systematic review
by: M. Anastasiou, et al.
Published: (2023-12-01)

Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors
by: Patrícia S. Sobral, et al.
Published: (2023-03-01)

Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies
by: Ismael Rodriguez, et al.
Published: (2023-09-01)

Gut microbiome for predicting immune checkpoint blockade-associated adverse events
by: Muni Hu, et al.
Published: (2024-01-01)

Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward
by: Shinada K, et al.
Published: (2023-02-01)

Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment
by: Muhammad Joan Ailia, et al.
Published: (2023-03-01)

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
by: Andrzej Kowalski, et al.
Published: (2021-07-01)

Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?
by: Vasiliki Siozopoulou, et al.
Published: (2021-01-01)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
by: Walid Shalata, et al.
Published: (2021-10-01)

Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
by: Ahmad Monabati, et al.
Published: (2020-07-01)

Advances in Promoting the Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Hepatocellular Carcinoma
by: Jie Shen, et al.
Published: (2022-10-01)

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%
by: Wei Chen, et al.
Published: (2023-08-01)

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment
by: Suxia Geng, et al.
Published: (2022-08-01)

Understanding and overcoming resistance to immunotherapy in genitourinary cancers
by: Sean T Evans, et al.
Published: (2024-12-01)

Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review
by: Maryam Noori, et al.
Published: (2024-01-01)

B7-H3 immunoregulatory roles in cancer
by: Keywan Mortezaee
Published: (2023-07-01)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
by: Wei Shi, et al.
Published: (2023-05-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer
by: Magdalena Bojko, et al.
Published: (2024-04-01)

Research progress of immune checkpoint inhibitors in the treatment of metastatic colorectal cancer
by: TU Juanjuan, et al.
Published: (2023-02-01)

Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors
by: Peter L. Stern, et al.
Published: (2021-06-01)

Camrelizumab plus zoledronic acid showed sustained efficacy in a patient with cranial and spinal metastases from lung adenocarcinoma
by: Chu Zhang, et al.
Published: (2021-06-01)

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
by: Sven H. Loosen, et al.
Published: (2021-03-01)

PD-1 and PD-L1 Expression in Indian Women with Breast Cancer
by: Kishan R. Bharadwa, et al.
Published: (2022-01-01)

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy
by: Mohammadsaleh Jahangir, et al.
Published: (2022-12-01)

Immunohistochemical Expression of Programmed Cell Death Ligand 1 (PD-L1) in Human Cutaneous Malignant Melanoma: A Narrative Review with Historical Perspectives
by: Gerardo Cazzato, et al.
Published: (2023-06-01)

Immunohistochemical Evaluation of Renal Biopsy with Anti-PD1 and p53 to Solve the Dilemma between Platinum- and Pembrolizumab-Induced AKI: Case Report and Review
by: Nicoletta Mancianti, et al.
Published: (2024-03-01)

Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
by: Koichi Furukawa, et al.
Published: (2020-08-01)

Defective Induction of IL-27-Mediated Immunoregulation by Myeloid DCs in Multiple Sclerosis
by: Felipe von Glehn, et al.
Published: (2023-04-01)

Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management
by: Dani Ran Castillo, et al.
Published: (2023-07-01)

Difference between Keratinized- and Non-Keratinized-Originating Epithelium in the Process of Immune Escape of Oral Squamous Cell Carcinoma
by: Yoshiaki Kitsukawa, et al.
Published: (2024-03-01)